HC Wainwright reaffirmed their buy rating on shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in a research report sent to investors on Friday morning. HC Wainwright currently has a $6.00 target price on the biopharmaceutical company’s stock.
CPRX has been the topic of several other research reports. Piper Jaffray Companies set a $6.00 target price on shares of Catalyst Pharmaceuticals and gave the stock a buy rating in a report on Monday, August 7th. SunTrust Banks, Inc. reiterated a buy rating and issued a $5.00 target price on shares of Catalyst Pharmaceuticals in a report on Tuesday, September 5th. Roth Capital set a $5.00 target price on shares of Catalyst Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, November 1st. Finally, Zacks Investment Research upgraded shares of Catalyst Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, October 31st. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $5.50.
Shares of Catalyst Pharmaceuticals (NASDAQ CPRX) traded down $0.03 on Friday, reaching $2.90. 522,014 shares of the company traded hands, compared to its average volume of 874,287. Catalyst Pharmaceuticals has a 12-month low of $1.01 and a 12-month high of $3.24.
ILLEGAL ACTIVITY NOTICE: This report was originally published by BBNS and is the sole property of of BBNS. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://baseballnewssource.com/markets/catalyst-pharmaceuticals-inc-cprx-given-buy-rating-at-hc-wainwright/1775319.html.
In related news, insider Patrick J. Mcenany acquired 20,000 shares of the company’s stock in a transaction dated Tuesday, September 5th. The shares were bought at an average price of $2.58 per share, for a total transaction of $51,600.00. Following the acquisition, the insider now owns 4,471,026 shares in the company, valued at approximately $11,535,247.08. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 8.79% of the company’s stock.
Large investors have recently bought and sold shares of the company. Nationwide Fund Advisors bought a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter worth about $111,000. New York State Common Retirement Fund bought a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter worth about $114,000. State of Wisconsin Investment Board bought a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter worth about $149,000. SG Americas Securities LLC bought a new position in shares of Catalyst Pharmaceuticals during the 3rd quarter worth about $144,000. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Catalyst Pharmaceuticals by 1,861.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 63,114 shares of the biopharmaceutical company’s stock worth $175,000 after purchasing an additional 59,896 shares during the period. Institutional investors own 40.19% of the company’s stock.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.